Acne Drugs Companies, Growth and Development Strategy

Let's Explore the Top Companies in the Acne Drugs Market

Latest Companies Updates You Must Know:

Galderma

Headquarters: Switzerland
Latest Update: Galderma intends to invest in its Therapeutic Dermatology portfolio, particularly Nemluvio, and in its mature brands, capitalizing on its strong position in acne across international markets.

Johnson & Johnson Services, Inc.

Headquarters: United States
Latest Update: Johnson & Johnson is a global healthcare corporation focused on Innovative Medicine and MedTech.

GSK plc

Headquarters: United Kingdom
Latest Update: GSK aims to deliver a step-change in growth and performance over the next decade, driven by its high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline.

Pfizer Inc.

Headquarters: United States
Latest Update: Pfizer has completed an early-stage acne trial, indicating a gradual expansion in its dermatology portfolio.

AbbVie Inc.

Headquarters: United States
Latest Update: AbbVie announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib.

Sun Pharmaceutical Industries Ltd.

Headquarters: India
Latest Update: In November 2025, Sun Pharma announced the acquisition, at no cost, of the commercial sales rights to LEVULAN KERASTICK in Canada from Clarion Medical Technologies.

Bausch Health Companies Inc.

Headquarters: Finland
Latest Update: In July 2025, Bausch Health, Canada Inc. announced that PrCABTREO™ gel for the treatment of acne vulgaris is now available under public drug plans in Ontario and Nova Scotia, as well as through the federal Non-Insured Health Benefits (NIHB) drug plan.

Value Chain Analysis of the Acne Drugs Market

R&D

• R&D focuses on target identification, molecule screening, formulation development, stability testing, safety assessment, and scalability to create effective topical and oral acne treatments.
• Companies involved include Galderma, Johnson & Johnson, Sun Pharma, Bausch Health, and Almirall.

Clinical Trials & Regulatory Approvals

• Clinical trials and regulatory approvals involve preclinical studies, phased human trials, efficacy evaluation, safety monitoring, regulatory documentation, submissions, inspections, and post approval compliance.
• Companies involved include Pfizer, AbbVie, Galderma, IQVIA, and dermatology-focused CROs.

Distribution to Hospitals & Pharmacies

• Distribution to hospitals and pharmacies includes packaging, warehousing, wholesaler coordination, prescription fulfillment, logistics management, inventory control, and timely delivery to healthcare providers.
• Companies involved include McKesson, Cardinal Health, AmerisourceBergen, Walgreens Boots Alliance, and regional distributors.

Market Forecast

The global acne drugs market size was estimated at USD 10.24 billion in 2025 and is predicted to increase from USD 10.78 billion in 2026 to approximately USD 17.07 billion by 2035, expanding at a CAGR of 5.24% from 2026 to 2035.

Recent Developments in the Acne Drugs Market

• In August 2025, Revance is proud to introduce two novel additions to PanOxyl, expanding the brand’s renowned acne care portfolio with salicylic acid innovations: PanOxyl Acne Gel Wash and PanOxyl Daytime Invisible Patches.
• In April 2025, Sonoma Pharmaceuticals, Inc., announced the registration of its hypochlorous acid-based acne products with the Medicines & Healthcare products Regulatory Agency (MHRA) to be sold through a prominent U.K. 
• In October 2025, Dermata Therapeutics, Inc., a science-driven leader in dermatologic solutions, announced that the Australian Patent Office had accepted Dermata's patent application for its Spongilla technology combination as a method for treating acne.

Partner with our experts to explore the Acne Drugs Market at sales@towardshealthcare.com